Parkinson's Disease: Market Analysis and Forecasts, 2008-2012, 2017 & 2022
Visiongain is proud to announce the release of the brand new report "Parkinson's Diseases Market Analysis." In 2006, the global sales of PD therapeutics were $3.1bn up by 11% from $2.5bn in 2005.
London, United Kingdom, May 15, 2009 --(PR.com)-- Reports Details
Parkinson's disease (PD) is the second most common neurological disorder, affecting approximately 4.1m people worldwide. As the prevalence rate of PD is set to rise significantly in the coming years, clinical interventions will play a major role in combating the wide spectrum of unmet needs associated with the disease.
In 2006, the global sales of PD therapeutics were $3.1bn up by 11% from $2.5bn in 2005. Revenues of the only approved PD drugs across the major markets (US, Japan, France, Germany, Italy, Spain and the UK) totaled over $2.2bn in 2006, with revenues expected to exceed $4.6bn by 2012. With key some PD drugs expected to lose patent expiration in the near-term, visiongain predicts that the entry of new products will be inevitable. But which products will be successful and how much revenue will they generate? This report tells you.
The report analysis PD sales over the next 15 years and delivers the percentage market growth. The projected revenue growth will be driven largely by reformulations that will decrease the burden of polypharmacy in patients receiving PD pharmacotherapy. The leading therapeutics expected to change the PD market dynamics will include, GlaxoSmithKline's (GSK's) Requip Once-daily ER awaiting approval, UCB-Schwarz's Neupro, Teva and Lundbeck’s Azilect. How will these products effect you and your business?
Other key compounds predicted for success include Kyowa Hakko’s Istradefylline, Merck-Serono/Newron’s Safinamide. The new wave of Gene/cell Therapy compounds that have revealed positive initial clinical data, thus Neurotrophic growth factors (NGF), either to be injected directly into the brain are also tipped for potential market success. Ceregene’s Neuturine, Neurologix’ GAD (glutamic acid decarboxylase) amongst other similar drugs, will add to the present PD therapeutics that will expand revenue growth in the long-term.
With country-by-country focus on the markets of:
• US
• UK
• Germany
• Japan
• France
• Italy
• Spain
This report includes detailed five-year forecasts over the period 2008-2012, and Now features 10 and 15 year forecasts to help you understand the medium-term prospects for these markets.
Importance of the report:
This report features tables, graphs and charts, news, insights, the past and present developments in Market. This report will provide you with the complete understanding of the demand for a shift from modest therapies to highly efficacious drugs for the treatment of PD.
This visiongain report is the single authoritative and in-depth tool to equip you with the latest trends in all regional markets and why all (stakeholders) demand a new generation of drugs to improve the quality of live of suffers of PD and their caregivers. Visiongain recommends this astute and hard-hitting report with detailed information into the key market development and major players in the field.
Parkinson’s Disease Market Analysis & Forecasts 2008-2022 report is a must buy, because it presents in-depth and unbiased financial analysis for the near-term, medium-term and the long-term, market dynamics. When you buy the Visiongain 2008 PD report, you will be buying current and vital information on the vast array of compounds in pipeline that are marked for potential success in the long-term treatment of AD.
What questions does the report answer?
• Which regions have the highest prevalence of AD diseases today?
• Do you know the cost of PD across the larger markets?
• Who are the market leaders in this class of therapy?
• What market share was accounted for by the leading drugs in the major markets?
• Do you know how much the PD market will be worth by Q4 of 2007 and its potential value by 2012, 2017 and 2022?
• Which first line drugs will be coming off patent by 2012 and what are the economic implications to the market?
• Do you know the market Potential of Teva/Lundbeck’s Azilect?
• Do you know the Neuroprotective properties of Gene/cell Therapy compounds?
• Do you know which drugs have been withdrawn from the neurodegenerative market?
• Which molecules are currently in the PD pipelines that are deemed to answer unmet therapeutic needs in the future?
Companies Listed
Abbott
Aeolus
Alliance
Alseres
Amarin
Amgen
Antipodean
AstraZeneca
Avicena
Avigen
Bar
BarIlan University
Biogen Idec
Biomas
Boehringer Ingelheim
BristolMyersSquib
Britannia
Cell Genesys
Ceregene
Dainippon Sumitomo
Diamyd Medical
Eisai
Elan
Eli Lily
Faust Pharmaceutical
Forest
Fujomo
Genzyme
Georgetown University
Guilford
Juvantia
Kyowa Hakko
Lederle
Lunbeck
Max Planck Institute of Neurobiology
Medtronic
Meiji Seika
Merck KGaA
Merck Serono
Mertz
Merz
Mylan
National Patent Development
Neuren
Neurobiotics
NeuroCell
Neurologix
Newron
Novartis
ONO
Orion
Pfizer
Pharmaplaz
Phytrix
Prestwick
Roche
Samaritan
Sanofi-Aventis
Santhera
Schering-Plough
Schwarz Pharma
Scientific Testing
Siegfried
SkyePharma
Solvay
Syngis
The National Institute of Neurological Disorder and Stokes (NINDS
The New England Journal of Medicine
Valeant
Vernalis
Wyeth
Visiongain ltd.
4th Floor,
BSG House,
226 236 City Road,
London
EC1V 2QY
United Kingdom
Telephone: +44 (0) 20 7336 6100
Fax: +44 (0) 20 7549 9930
info@visiongainglobal.com
Or Visit at: http://www.visiongain.com/Report.aspx?rid=283
Or http://www.visiongain.com
###
Parkinson's disease (PD) is the second most common neurological disorder, affecting approximately 4.1m people worldwide. As the prevalence rate of PD is set to rise significantly in the coming years, clinical interventions will play a major role in combating the wide spectrum of unmet needs associated with the disease.
In 2006, the global sales of PD therapeutics were $3.1bn up by 11% from $2.5bn in 2005. Revenues of the only approved PD drugs across the major markets (US, Japan, France, Germany, Italy, Spain and the UK) totaled over $2.2bn in 2006, with revenues expected to exceed $4.6bn by 2012. With key some PD drugs expected to lose patent expiration in the near-term, visiongain predicts that the entry of new products will be inevitable. But which products will be successful and how much revenue will they generate? This report tells you.
The report analysis PD sales over the next 15 years and delivers the percentage market growth. The projected revenue growth will be driven largely by reformulations that will decrease the burden of polypharmacy in patients receiving PD pharmacotherapy. The leading therapeutics expected to change the PD market dynamics will include, GlaxoSmithKline's (GSK's) Requip Once-daily ER awaiting approval, UCB-Schwarz's Neupro, Teva and Lundbeck’s Azilect. How will these products effect you and your business?
Other key compounds predicted for success include Kyowa Hakko’s Istradefylline, Merck-Serono/Newron’s Safinamide. The new wave of Gene/cell Therapy compounds that have revealed positive initial clinical data, thus Neurotrophic growth factors (NGF), either to be injected directly into the brain are also tipped for potential market success. Ceregene’s Neuturine, Neurologix’ GAD (glutamic acid decarboxylase) amongst other similar drugs, will add to the present PD therapeutics that will expand revenue growth in the long-term.
With country-by-country focus on the markets of:
• US
• UK
• Germany
• Japan
• France
• Italy
• Spain
This report includes detailed five-year forecasts over the period 2008-2012, and Now features 10 and 15 year forecasts to help you understand the medium-term prospects for these markets.
Importance of the report:
This report features tables, graphs and charts, news, insights, the past and present developments in Market. This report will provide you with the complete understanding of the demand for a shift from modest therapies to highly efficacious drugs for the treatment of PD.
This visiongain report is the single authoritative and in-depth tool to equip you with the latest trends in all regional markets and why all (stakeholders) demand a new generation of drugs to improve the quality of live of suffers of PD and their caregivers. Visiongain recommends this astute and hard-hitting report with detailed information into the key market development and major players in the field.
Parkinson’s Disease Market Analysis & Forecasts 2008-2022 report is a must buy, because it presents in-depth and unbiased financial analysis for the near-term, medium-term and the long-term, market dynamics. When you buy the Visiongain 2008 PD report, you will be buying current and vital information on the vast array of compounds in pipeline that are marked for potential success in the long-term treatment of AD.
What questions does the report answer?
• Which regions have the highest prevalence of AD diseases today?
• Do you know the cost of PD across the larger markets?
• Who are the market leaders in this class of therapy?
• What market share was accounted for by the leading drugs in the major markets?
• Do you know how much the PD market will be worth by Q4 of 2007 and its potential value by 2012, 2017 and 2022?
• Which first line drugs will be coming off patent by 2012 and what are the economic implications to the market?
• Do you know the market Potential of Teva/Lundbeck’s Azilect?
• Do you know the Neuroprotective properties of Gene/cell Therapy compounds?
• Do you know which drugs have been withdrawn from the neurodegenerative market?
• Which molecules are currently in the PD pipelines that are deemed to answer unmet therapeutic needs in the future?
Companies Listed
Abbott
Aeolus
Alliance
Alseres
Amarin
Amgen
Antipodean
AstraZeneca
Avicena
Avigen
Bar
BarIlan University
Biogen Idec
Biomas
Boehringer Ingelheim
BristolMyersSquib
Britannia
Cell Genesys
Ceregene
Dainippon Sumitomo
Diamyd Medical
Eisai
Elan
Eli Lily
Faust Pharmaceutical
Forest
Fujomo
Genzyme
Georgetown University
Guilford
Juvantia
Kyowa Hakko
Lederle
Lunbeck
Max Planck Institute of Neurobiology
Medtronic
Meiji Seika
Merck KGaA
Merck Serono
Mertz
Merz
Mylan
National Patent Development
Neuren
Neurobiotics
NeuroCell
Neurologix
Newron
Novartis
ONO
Orion
Pfizer
Pharmaplaz
Phytrix
Prestwick
Roche
Samaritan
Sanofi-Aventis
Santhera
Schering-Plough
Schwarz Pharma
Scientific Testing
Siegfried
SkyePharma
Solvay
Syngis
The National Institute of Neurological Disorder and Stokes (NINDS
The New England Journal of Medicine
Valeant
Vernalis
Wyeth
Visiongain ltd.
4th Floor,
BSG House,
226 236 City Road,
London
EC1V 2QY
United Kingdom
Telephone: +44 (0) 20 7336 6100
Fax: +44 (0) 20 7549 9930
info@visiongainglobal.com
Or Visit at: http://www.visiongain.com/Report.aspx?rid=283
Or http://www.visiongain.com
###
Contact
Visiongain Ltd.
Suvitha Damodaran
+44 (0) 20 7336 6100
http://www.visiongain.com
Suvitha Damodaran
+44 (0) 20 7336 6100
http://www.visiongain.com
Contact
Categories